Browse H2AFZ

Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Chromosome.
Domain PF00125 Core histone H2A/H2B/H3/H4
PF16211 C-terminus of histone H2A
Function

Variant histone H2A which replaces conventional H2A in a subset of nucleosomes. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. May be involved in the formation of constitutive heterochromatin. May be required for chromosome segregation during cell division.

> Gene Ontology
 
Biological Process GO:0006342 chromatin silencing
GO:0016458 gene silencing
GO:0032355 response to estradiol
GO:0040029 regulation of gene expression, epigenetic
GO:0045814 negative regulation of gene expression, epigenetic
GO:0071392 cellular response to estradiol stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001159 core promoter proximal region DNA binding
GO:0003682 chromatin binding
GO:0031490 chromatin DNA binding
GO:0031491 nucleosome binding
GO:0031492 nucleosomal DNA binding
GO:0035326 enhancer binding
GO:0043566 structure-specific DNA binding
GO:0046982 protein heterodimerization activity
Cellular Component GO:0000785 chromatin
GO:0000786 nucleosome
GO:0000790 nuclear chromatin
GO:0000791 euchromatin
GO:0000792 heterochromatin
GO:0005719 nuclear euchromatin
GO:0005720 nuclear heterochromatin
GO:0032993 protein-DNA complex
GO:0044454 nuclear chromosome part
GO:0044815 DNA packaging complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5625886: Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
R-HSA-5619507: Activation of HOX genes during differentiation
R-HSA-5617472: Activation of anterior HOX genes in hindbrain development during early embryogenesis
R-HSA-977225: Amyloid fiber formation
R-HSA-5250924: B-WICH complex positively regulates rRNA expression
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-73886: Chromosome Maintenance
R-HSA-2299718: Condensation of Prophase Chromosomes
R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence
R-HSA-5334118: DNA methylation
R-HSA-606279: Deposition of new CENPA-containing nucleosomes at the centromere
R-HSA-1266738: Developmental Biology
R-HSA-427389: ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-201722: Formation of the beta-catenin
R-HSA-74160: Gene Expression
R-HSA-211000: Gene Silencing by RNA
R-HSA-68886: M Phase
R-HSA-1500620: Meiosis
R-HSA-912446: Meiotic recombination
R-HSA-1221632: Meiotic synapsis
R-HSA-392499: Metabolism of proteins
R-HSA-68875: Mitotic Prophase
R-HSA-5250941: Negative epigenetic regulation of rRNA expression
R-HSA-427413: NoRC negatively regulates rRNA expression
R-HSA-774815: Nucleosome assembly
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-212300: PRC2 methylates histones and DNA
R-HSA-171306: Packaging Of Telomere Ends
R-HSA-5250913: Positive epigenetic regulation of rRNA expression
R-HSA-195258: RHO GTPase Effectors
R-HSA-5625740: RHO GTPases activate PKNs
R-HSA-3214858: RMTs methylate histone arginines
R-HSA-73777: RNA Polymerase I Chain Elongation
R-HSA-73854: RNA Polymerase I Promoter Clearance
R-HSA-73728: RNA Polymerase I Promoter Opening
R-HSA-73864: RNA Polymerase I Transcription
R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
R-HSA-427359: SIRT1 negatively regulates rRNA Expression
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-157579: Telomere Maintenance
R-HSA-5578749: Transcriptional regulation by small RNAs
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between H2AFZ and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of H2AFZ in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.55 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of H2AFZ in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0980.757
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2070.959
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0210.994
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0120.97
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1290.937
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1870.93
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2210.663
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5290.817
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0960.97
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0310.989
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0790.983
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3090.000408
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of H2AFZ in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of H2AFZ. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of H2AFZ. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by H2AFZ.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of H2AFZ. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of H2AFZ expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between H2AFZ and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolH2AFZ
NameH2A histone family, member Z
Aliases H2A.Z; H2AZ; H2A.Z-1; H2A/z; H2AZ histone; Histone H2A.Z
Chromosomal Location4q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting H2AFZ collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.